Amgen's Repatha shows reduced heart attack risk while Satellos alters Duchenne trial endpoint
Satellos Bioscience announced a change to the primary endpoint of its ongoing Duchenne muscular dystrophy trial of the investigational small‑molecule forazapadin, shifting focus to a measure of muscle repair and growth in boys with the disease.
The adjustment reflects the company's effort to better capture therapeutic benefit and may affect timelines for data readout.
In separate news, Amgen reported that its PCSK9 inhibitor Repatha significantly lowered the risk of heart attack in a recent cardiovascular outcomes study, reinforcing its role in lipid management.
The briefing also noted brief updates from MetaVia, Agios Pharmaceuticals and Inovio, though no specific details were provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that